Intravitreal Bevasizumab Versus Intravitreal Triamcinolone in Central Retinal Vein Occlusion (CRVO)

NCT01178697 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

OTHER

Sponsor class

Conditions

Central Retinal Vein Occlusion

Interventions

DRUG: Bevasizumab
DRUG: Triamcinolone Acetonide

Sponsor

Shahid Beheshti University of Medical Sciences

Collaborators

[object Object]